Literature DB >> 9494866

Applications of magnetic resonance spectroscopy to diagnosis and monitoring of mitochondrial disease.

P M Matthews1, T Taivassalo.   

Abstract

Magnetic resonance spectroscopy (MRS) can now be performed on routine high-field clinical magnetic resonance imaging systems. Over the last decade it has provided several useful insights into the pathophysiology of mitochondrial disorders. More recently, the feasibility of applications to clinical diagnosis and monitoring have been demonstrated. Exciting new work suggests that carefully supervised physical conditioning in conjunction with sodium dichloroacetate administration can markedly enhance both biochemical measures of aerobic metabolism and functional performance of patients with mitochondrial myopathies.

Entities:  

Mesh:

Year:  1997        PMID: 9494866     DOI: 10.1007/BF02048237

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  21 in total

1.  Magnetic resonance imaging shows specific abnormalities in the MELAS syndrome.

Authors:  P M Matthews; D Tampieri; S F Berkovic; F Andermann; K Silver; D Chityat; D L Arnold
Journal:  Neurology       Date:  1991-07       Impact factor: 9.910

2.  Coenzyme Q.

Authors:  P M Matthews; D L Arnold
Journal:  Neurology       Date:  1993-03       Impact factor: 9.910

3.  A 31P-NMR study of some metabolic and functional effects of the inotropic agents epinephrine and ouabain, and the ionophore R02-2985 (X537A) in the isolated, perfused rat heart.

Authors:  P M Matthews; S R Williams; A M Seymour; A Schwartz; G Dube; D G Gadian; G K Radda
Journal:  Biochim Biophys Acta       Date:  1982-04-29

4.  31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle.

Authors:  S Eleff; N G Kennaway; N R Buist; V M Darley-Usmar; R A Capaldi; W J Bank; B Chance
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

5.  Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR.

Authors:  D L Arnold; P M Matthews; G K Radda
Journal:  Magn Reson Med       Date:  1984-09       Impact factor: 4.668

6.  Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: A 31P-NMR follow-up study.

Authors:  Z Argov; W J Bank; J Maris; S Eleff; N G Kennaway; R E Olson; B Chance
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

7.  Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease.

Authors:  P M Matthews; B Ford; R J Dandurand; D H Eidelman; D O'Connor; A Sherwin; G Karpati; F Andermann; D L Arnold
Journal:  Neurology       Date:  1993-05       Impact factor: 9.910

8.  Cerebral dysgenesis and lactic acidemia: an MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency.

Authors:  M I Shevell; P M Matthews; C R Scriver; R M Brown; L J Otero; M Legris; G K Brown; D L Arnold
Journal:  Pediatr Neurol       Date:  1994-10       Impact factor: 3.372

9.  Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders.

Authors:  N De Stefano; P M Matthews; B Ford; A Genge; G Karpati; D L Arnold
Journal:  Neurology       Date:  1995-06       Impact factor: 9.910

Review 10.  Correlative multidisciplinary approach to the study of mitochondrial encephalomyopathies.

Authors:  G Karpati; D Arnold; P Matthews; S Carpenter; F Andermann; E Shoubridge
Journal:  Rev Neurol (Paris)       Date:  1991       Impact factor: 2.607

View more
  2 in total

Review 1.  Diagnosis and treatment of childhood mitochondrial diseases.

Authors:  A L Gropman
Journal:  Curr Neurol Neurosci Rep       Date:  2001-03       Impact factor: 6.030

Review 2.  Radiation-induced heart disease: a review of classification, mechanism and prevention.

Authors:  Heru Wang; Jinlong Wei; Qingshuang Zheng; Lingbin Meng; Ying Xin; Xia Yin; Xin Jiang
Journal:  Int J Biol Sci       Date:  2019-08-08       Impact factor: 6.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.